Marked decrease in the incidence and prevalence of hepatitis A in the Basque Country, Spain, 1986-2004

Epidemiology and Infection

Volumn 135, Issue 3, 2007, Pages 402-408

  Cilla, G ^a   Perez Trallero E ^a,b   Artieda, J ^c   Serrano Bengoechea, E ^a   Montes, M ^a   Vicente, D ^a  

^a HOSPITAL DONOSTIA   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^c Unidad de Epidemiología   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A VACCINE;

ADOLESCENT; ADULT; AGE; ANTIBODY TITER; ARTICLE; CHILD; CONTROLLED STUDY; ENDEMIC DISEASE; FEMALE; HEPATITIS A; HOSPITALIZATION; HUMAN; INCIDENCE; INFANT; INFECTION RISK; MAJOR CLINICAL STUDY; PREVALENCE; RISK FACTOR; SEROPREVALENCE; SPAIN; STATISTICAL SIGNIFICANCE; VACCINATION;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; HEPATITIS A; HEPATITIS A ANTIBODIES; HOSPITALIZATION; HUMANS; IMMUNOGLOBULIN G; INCIDENCE; INFANT; MALE; MIDDLE AGED; PREVALENCE; SPAIN; TIME FACTORS;

EID: 33947371217     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268806006959     Document Type: Article

References (25)

1. World Health Organization. Hepatitis A vaccines. WHO position paper. Weekly Epidemiological Record 2000; 75: 38-44.
2. CDC. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report 1999; 48: 1-37.
3. Almasio PL, Amoroso P. HAV infection in chronic liver disease: A rationale for vaccination. Vaccine 2003; 21: 2238-2241.
4. Van Damme P, et al. Hepatitis A booster vaccination: Is there a need? Lancet 2003; 362: 1065-1071.
5. Pérez-Trallero E, et al. Failing incidence and prevalence of hepatitis A in Northern Spain. Scandinavian Journal of Infectious Diseases 1994; 26: 133-136.
6. Begg NT, Gay NJ. Theory of infectious disease transmission and herd immunity, chapter 10. In: Collier L, Balows A, Sussman M (eds). Topley & Wilson's Microbiology and Microbial Infections, Vol. 3, Bacterial Infections, Hausler WJ, Sussman M, eds. 9th edn. London, 1998, pp. 147-165.
7. Departamento de Sanidad, Gobierno Vasco. Brote de hepatitis A en Gipuzkoa. Salud Pública 2001; 10 (semestre 1): 4. (http://www.osasun.ejgv.euskadi.net/r52-478/es/contenidos/informacion/ boletin_epidem/es_5482/adjuntos/10bolecast.pdf). Accessed 5 July 2006.
8. Dal-Ré R, García-Corbeira P, García-de-Lomas J. A large percentage of the spanish population under 30 years of age is not protected against hepatitis A. Journal of Medical Virology 2000; 60: 363-366.
9. Bruguera M, et al. Changes in the seroepidemiology of hepatitis A virus infection in Catalonia (Spain) from 1989 to 1996. Implications for a new vaccination strategy. Medicina Clinica (Barcelona) 1999; 112: 406-408.
10. Staes CJ, et al. Sources of infection among persons with acute hepatitis A and no identified risk factors during a sustained community wide outbreak. Pediatrics 2000; 106: E54.
11. Wasley A, Samandari T, Bell BP. Incidence of hepatitis A in the United States in the era of vaccination. Journal of the American Medical Association 2005; 294: 194-201.
12. Crowcroft NS, et al. PHLS Advisory Committee on Vaccination and Immunisation. Guidelines for the control of hepatitis A virus infection. Communicable Disease and Public Health 2001; 4: 213-227.
13. Thierfelder W, et al. Prevalence of markers for hepatitis A, B and C in the German population. Results of the German National Health interview and examination survey 1998. European Journal of Epidemiology 2001; 17: 429-435.
14. Di Giammarino L, Dienstag JL. Hepatitis A - The price of progress. New England Journal of Medicine 2005; 353: 944-946.
15. D'Amelio R, et al. Hepatitis A, Italy. Emerging Infectious Diseases 2005; 11: 1155-1156.
16. Antunes H, Macedo M, Estrada A. Hepatitis A virus prevalence: Portuguese first results of low endemicity. Acta Medica Portuguesa 2004; 17: 219-224.
17. Franco E, Vitiello G. Vaccination strategies against hepatitis A in southern Europe. Vaccine 2003; 21: 696-697.
18. Jacobsen KH, Koopman JS. Declining hepatitis A seroprevalence: A global review and analysis. Epidemiology and Infection 2004; 132: 1005-1022.
19. Jacobsen KH, Koopman JS. The effects of socioeconomic development on worldwide hepatitis A virus seroprevalence patterns. International Journal of Epidemiology 2005; 34: 600-609.
20. Amela C, et al. Trends in hepatitis A virus infection with reference to the process of urbanization in the greater Madrid area (Spain). European Journal of Epidemiology 1995; 11: 569-573.
21. Dagan R, et al. Incidence of hepatitis A in Israel following universal immunization of toddlers. Journal of the American Medical Association 2005; 294: 202-210.
22. CDC. Recommended childhood and adolescent immunization schedule: United States, 2006. Morbidity and Mortality Weekly Report 2006; 54: Q1-Q4.
23. Lopalco PL, et al. Hepatitis A and B in children and adolescents - what can we learn from Puglia (Italy) and Catalonia (Spain)? Vaccine 2001; 19: 470-474.
24. Domínguez A, et al. Prevalence of hepatitis A antibodies in schoolchildren in Catalonia (Spain) after the introduction of universal hepatitis A immunization. Journal of Medical Virology 2004; 73: 172-176.
25. Steenbergen JE, et al. Two years' prospective collection of molecular and epidemiological data shows limited spread of hepatitis A virus outside risk groups in Amsterdam, 2000-2002. Journal of Infectious Diseases 2004; 189: 471-482.